Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Moderately to Severely Active Ulcerative Colitis
NCT04033445Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2019
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 34
01
Overview
A Phase 3 trial of guselkumab in ulcerative colitis (UC), sponsored by Janssen Pharmaceutical. Started Sep 2019; status: active, not recruiting.
02
Drugs
guselkumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04033445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04033445.